The Agence nationale de sécurité du médicament et des produits de santé may, after obtaining the opinion of the Etablissement français du sang and the armed forces blood transfusion centre, regulate the use of labile blood products. The Agency may impose special conditions, restrict, suspend or prohibit their use in the interests of public health.